A US appeals court on Friday, February 21, revived a lawsuit by Walgreen and Kroger accusing Johnson & Johnson (J&J) of unlawfully restricting access to lower-cost “biosimilar” versions of its drug Remicade.
Reversing a lower court, the 3rd US Circuit Court of Appeals stated contracts Walgreens and Kroger entered into with drug wholesalers gave the pharmacies the right to sue J&J for antitrust violations.
The retailers had lodged their suit in Pennsylvania federal court last year, accusing J&J of illegally shielding its blockbuster drug from competitors and charging artificially inflated prices for the treatment. Their suit cited the same core allegations that had sparked earlier legal action from other players in the pharmaceutical industry, including one from rival drugmaker Pfizer and a proposed class suit lodged by other buyers along the Remicade distribution line.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI